Table 1.
Plasma Hormone Levels in Control Rats and in Rats Treated With Spironolactone and Potassium Canrenoate
Control group 1 | Spironolactone group 2 | pa | Potassium canrenoate group 3 | pa | |
---|---|---|---|---|---|
Testosterone (ng/ml) | 1.8 ± 0.32 | 0.80 ± 0.24 | <0.05 | 1.5 ± 0.30 | NS |
Estradiol (pg/ml) | 9.8 ± 1.2 | 7.9 ± 2.1 | NS | 9.6 ± 1.1 | NS |
Estriol (ng/ml) | 1.26 ± 0.48 | 1.68 ± 0.69 | NS | 1.18 ± 0.39 | NS |
Progesterone (ng/ml) | 3.93 ± 0.27 | 3.21 ± 0.53 | NS | 2.71 ± 0.38 | <0.05 |
DHEAS (ng/ml) | 99.60 ± 22.3 | 105.0 ± 22.4 | NS | 38.6 ± 15.3 | <0.05 |
FSH (mU/ml) | 1.75 ± 0.34 | 2.46 ± 0.37 | NS | 1.19 ± 0.25 | NS |
PRL (mU/ml) | 7.02 ± 0.77 | 6.8 ± 0.3 | NS | 5.95 ± 0.60 | NS |
LH (mU/ml) | 6.52 ± 1.02 | 4.76 ± 0.8 | NS | 4.93 ± 0.93 | NS |
DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-stimulating hormone; LH, luteinizing hormone; NS, not significant; PRL, prolactin. Group 1 was treated with vehicle. The other groups received spironolactone (group 2) and potassium canrenoate (group 3) at the dosage of 5 mg/day for 21 days. Values are expressed as mean ± SD.
Values that differ from control values.